Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 523 (7559), 231-5

Melanoma-intrinsic β-Catenin Signalling Prevents Anti-Tumour Immunity

Affiliations

Melanoma-intrinsic β-Catenin Signalling Prevents Anti-Tumour Immunity

Stefani Spranger et al. Nature.

Abstract

Melanoma treatment is being revolutionized by the development of effective immunotherapeutic approaches. These strategies include blockade of immune-inhibitory receptors on activated T cells; for example, using monoclonal antibodies against CTLA-4, PD-1, and PD-L1 (refs 3-5). However, only a subset of patients responds to these treatments, and data suggest that therapeutic benefit is preferentially achieved in patients with a pre-existing T-cell response against their tumour, as evidenced by a baseline CD8(+) T-cell infiltration within the tumour microenvironment. Understanding the molecular mechanisms that underlie the presence or absence of a spontaneous anti-tumour T-cell response in subsets of cases, therefore, should enable the development of therapeutic solutions for patients lacking a T-cell infiltrate. Here we identify a melanoma-cell-intrinsic oncogenic pathway that contributes to a lack of T-cell infiltration in melanoma. Molecular analysis of human metastatic melanoma samples revealed a correlation between activation of the WNT/β-catenin signalling pathway and absence of a T-cell gene expression signature. Using autochthonous mouse melanoma models we identified the mechanism by which tumour-intrinsic active β-catenin signalling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy. Specific oncogenic signals, therefore, can mediate cancer immune evasion and resistance to immunotherapies, pointing to new candidate targets for immune potentiation.

Comment in

Similar articles

See all similar articles

Cited by 525 articles

See all "Cited by" articles

References

    1. N Engl J Med. 2013 Jul 11;369(2):122-33 - PubMed
    1. J Immunol. 2010 Jul 1;185(1):738-47 - PubMed
    1. J Immunol. 2012 Sep 1;189(5):2110-7 - PubMed
    1. Nat Rev Clin Oncol. 2013 Oct;10(10):588-98 - PubMed
    1. Genesis. 2006 May;44(5):262-7 - PubMed

Publication types

Associated data

Feedback